Mediwound Stock Net Income
| MDWD Stock | USD 17.65 0.77 4.18% |
As of the 29th of January, Mediwound secures the Downside Deviation of 2.61, mean deviation of 1.77, and Risk Adjusted Performance of 0.014. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mediwound, as well as the relationship between them. Please verify Mediwound treynor ratio, and the relationship between the standard deviation and downside variance to decide if Mediwound is priced some-what accurately, providing market reflects its recent price of 17.65 per share. Given that Mediwound has jensen alpha of (0.02), we recommend you to check Mediwound's last-minute market performance to make sure the company can sustain itself at a future point.
Mediwound Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 8.8793 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.2 M | -25.8 M | |
| Net Loss | -17.6 M | -18.5 M | |
| Net Loss | -27.2 M | -25.8 M | |
| Net Loss | (2.73) | (2.87) | |
| Net Income Per E B T | 1.15 | 1.30 |
Mediwound | Net Income | Build AI portfolio with Mediwound Stock |
Latest Mediwound's Net Income Growth Pattern
Below is the plot of the Net Income of Mediwound over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Mediwound financial statement analysis. It represents the amount of money remaining after all of Mediwound operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Mediwound's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mediwound's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (30.22 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Mediwound Net Income Regression Statistics
| Arithmetic Mean | (13,363,360) | |
| Coefficient Of Variation | (86.37) | |
| Mean Deviation | 9,427,238 | |
| Median | (15,351,000) | |
| Standard Deviation | 11,541,391 | |
| Sample Variance | 133.2T | |
| Range | 41.2M | |
| R-Value | (0.47) | |
| Mean Square Error | 110.6T | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | (1,076,520) | |
| Total Sum of Squares | 2131.3T |
Mediwound Net Income History
Other Fundumenentals of Mediwound
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Mediwound Net Income component correlations
Mediwound Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Mediwound is extremely important. It helps to project a fair market value of Mediwound Stock properly, considering its historical fundamentals such as Net Income. Since Mediwound's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mediwound's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mediwound's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Mediwound diversify its offerings? Factors like these will boost the valuation of Mediwound. Expected growth trajectory for Mediwound significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mediwound data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.84) | Revenue Per Share | Quarterly Revenue Growth 0.247 | Return On Assets | Return On Equity |
Investors evaluate Mediwound using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mediwound's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mediwound's market price to deviate significantly from intrinsic value.
Understanding that Mediwound's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mediwound represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mediwound's market price signifies the transaction level at which participants voluntarily complete trades.
Mediwound 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mediwound's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mediwound.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Mediwound on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Mediwound or generate 0.0% return on investment in Mediwound over 90 days. Mediwound is related to or competes with NeOnc Technologies, Genfit SA, Sellas Life, Protara Therapeutics, Invivyd, Orchestra BioMed, and Cartesian Therapeutics. MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic soluti... More
Mediwound Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mediwound's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mediwound upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.61 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 14.07 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 3.79 |
Mediwound Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mediwound's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mediwound's standard deviation. In reality, there are many statistical measures that can use Mediwound historical prices to predict the future Mediwound's volatility.| Risk Adjusted Performance | 0.014 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0277 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mediwound's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mediwound January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.014 | |||
| Market Risk Adjusted Performance | 0.0377 | |||
| Mean Deviation | 1.77 | |||
| Semi Deviation | 2.52 | |||
| Downside Deviation | 2.61 | |||
| Coefficient Of Variation | 10459.27 | |||
| Standard Deviation | 2.46 | |||
| Variance | 6.05 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0277 | |||
| Maximum Drawdown | 14.07 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 3.79 | |||
| Downside Variance | 6.79 | |||
| Semi Variance | 6.36 | |||
| Expected Short fall | (1.90) | |||
| Skewness | (0.55) | |||
| Kurtosis | 1.71 |
Mediwound Backtested Returns
At this point, Mediwound is very steady. Mediwound has Sharpe Ratio of 0.0159, which conveys that the firm had a 0.0159 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Mediwound, which you can use to evaluate the volatility of the firm. Please verify Mediwound's Downside Deviation of 2.61, mean deviation of 1.77, and Risk Adjusted Performance of 0.014 to check out if the risk estimate we provide is consistent with the expected return of 0.0404%. Mediwound has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.49, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mediwound's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mediwound is expected to be smaller as well. Mediwound right now secures a risk of 2.55%. Please verify Mediwound downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to decide if Mediwound will be following its current price movements.
Auto-correlation | 0.06 |
Virtually no predictability
Mediwound has virtually no predictability. Overlapping area represents the amount of predictability between Mediwound time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mediwound price movement. The serial correlation of 0.06 indicates that barely 6.0% of current Mediwound price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.66 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Mediwound Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Mediwound reported net income of (30.22 Million). This is 108.86% lower than that of the Pharmaceuticals sector and 143.15% lower than that of the Health Care industry. The net income for all United States stocks is 105.29% higher than that of the company.
Mediwound Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mediwound's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics of similar companies.Mediwound is currently under evaluation in net income category among its peers.
Mediwound ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mediwound's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mediwound's managers, analysts, and investors.Environmental | Governance | Social |
Mediwound Institutional Holders
Institutional Holdings refers to the ownership stake in Mediwound that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mediwound's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mediwound's value.| Shares | Balyasny Asset Management Llc | 2025-06-30 | 75.6 K | Ubs Group Ag | 2025-06-30 | 66.2 K | Dafna Capital Management Llc | 2025-06-30 | 64.5 K | Sargent Investment Group, Llc | 2025-06-30 | 53.9 K | Vanguard Group Inc | 2025-06-30 | 53.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 48.2 K | Legato Capital Management Llc | 2025-06-30 | 43.2 K | Millennium Management Llc | 2025-06-30 | 38.5 K | Citadel Advisors Llc | 2025-06-30 | 32.1 K | Investors Finance Co Plc | 2025-06-30 | 872.1 K | Yelin Lapidot Holdings Management Ltd | 2025-06-30 | 816.7 K |
Mediwound Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.98) % | ||||
| Operating Margin | (1.20) % | ||||
| Current Valuation | 185.86 M | ||||
| Shares Outstanding | 12.84 M | ||||
| Shares Owned By Insiders | 15.13 % | ||||
| Shares Owned By Institutions | 53.80 % | ||||
| Number Of Shares Shorted | 1.06 M | ||||
| Price To Earning | 16.58 X | ||||
| Price To Book | 4.72 X | ||||
| Price To Sales | 11.29 X | ||||
| Revenue | 20.22 M | ||||
| Gross Profit | 3.88 M | ||||
| EBITDA | (28.12 M) | ||||
| Net Income | (30.22 M) | ||||
| Cash And Equivalents | 10.41 M | ||||
| Cash Per Share | 0.31 X | ||||
| Total Debt | 6.93 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.61 X | ||||
| Book Value Per Share | 3.91 X | ||||
| Cash Flow From Operations | (13.62 M) | ||||
| Short Ratio | 11.37 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 31.5 | ||||
| Number Of Employees | 111 | ||||
| Beta | 0.075 | ||||
| Market Capitalization | 236.42 M | ||||
| Total Asset | 73.5 M | ||||
| Retained Earnings | (205.05 M) | ||||
| Working Capital | 25.62 M | ||||
| Current Asset | 50.4 M | ||||
| Current Liabilities | 5.21 M | ||||
| Net Asset | 73.5 M |
About Mediwound Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mediwound is a strong investment it is important to analyze Mediwound's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mediwound's future performance. For an informed investment choice regarding Mediwound Stock, refer to the following important reports:Check out Mediwound Piotroski F Score and Mediwound Altman Z Score analysis. For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Pharmaceuticals sector continue expanding? Could Mediwound diversify its offerings? Factors like these will boost the valuation of Mediwound. Expected growth trajectory for Mediwound significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mediwound data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.84) | Revenue Per Share | Quarterly Revenue Growth 0.247 | Return On Assets | Return On Equity |
Investors evaluate Mediwound using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mediwound's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mediwound's market price to deviate significantly from intrinsic value.
Understanding that Mediwound's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mediwound represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mediwound's market price signifies the transaction level at which participants voluntarily complete trades.